sFlt-1:PlGF Ratio in Diagnosing Superimposed Preeclampsia

Plain-language summary

This study examined the value of the sFlt-1:PlGF blood marker ratio in diagnosing superimposed preeclampsia in pregnant women with chronic high blood pressure. It included pregnant women between 20 and 38 weeks of gestation with a diagnosis of chronic hypertension. It was a non-phase study that has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University of Tennessee

Start date

2/1/2016

Estimated completion

6/30/2020

Countries

United States

Related genes

Locations

• Memphis, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Gestational age at enrollment: 20 0/7 weeks to 38 6/7 weeks gestation Pregnant women aged 14 to 45 years
* Presenting for admission for suspected superimposed preeclampsia
* Diagnosis of chronic hypertension made prenatally or in the first 20 weeks of pregnancy (+/- medical therapy)
* The clinical diagnosis of preeclampsia will follow the current criteria outlined by ACOG 10.

Exclusion Criteria:

* Age 45 years;
* Gestational age 19 6/7 weeks or less or 39 weeks or more ;
* Multiple gestations.